Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis is interested in acquiring a company with market cap up to $20 billion, CEO Viehbacher says, leaving open the possibility of acquiring Genzyme.
You may also be interested in...
Genzyme/Isis On Track To Submit Cholesterol Drug Mipomersen In 1H 2011
Mipomersen, Genzyme/Isis Pharmaceuticals' second-generation antisense drug for severe high cholesterol, is four for four in terms of collecting positive outcomes in Phase III trials. But in addition to lowered cholesterol, patients in all of those studies had elevated liver enzymes, leaving open the question whether regulators will consider the side effect a manageable trade off for filling an unmet medical need
Genzyme/Isis On Track To Submit Cholesterol Drug Mipomersen In 1H 2011
Mipomersen, Genzyme/Isis Pharmaceuticals' second-generation antisense drug for severe high cholesterol, is four for four in terms of collecting positive outcomes in Phase III trials. But in addition to lowered cholesterol, patients in all of those studies had elevated liver enzymes, leaving open the question whether regulators will consider the side effect a manageable trade off for filling an unmet medical need
Genzyme/Isis On Track To Submit Severe High Cholesterol Drug Mipomersen In 1H 2011
The second-generation antisense drug is four for four in positive Phase III outcomes, but in addition to lowered cholesterol, patients in those studies had elevated liver enzymes, leaving observers to wonder whether FDA will consider the side effect a manageable trade-off for filling an unmet need.